Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva is a financially stable healthcare company with diverse revenue streams and a strong focus on antibiotic stewardship. Their patented products have shown promising results in critical care and infectious disease, and their recent acquisition of an extended release platform for oral small molecules positions them for continued success in the future. With the potential for new treatments and a focus on increasing the use of their existing products, Innoviva is a strong investment opportunity in the healthcare industry.

Bears say

Innoviva is placing a heavy emphasis on its partnership with Armata and its potential for success in Phase 3 trials which is not projected to occur until 2026, indicating a long-term outlook. Additionally, the company's current product offerings and strategic assets have not been able to generate significant revenue or profits, potentially hindering future growth. The economic burden and challenges of treating antibiotic-resistant infections also pose long-term risks for the company if its products are not successful in addressing this issue.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.